Davis's Drug Guide
Tri-Sprintec
Phase I
norgestimate 0.18 mg + ethinyl estradiol 35 mcg
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Tri-Sprintec." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/61555/all/Tri_Sprintec.
Vallerand AHA, Sanoski CAC, Quiring CC. Tri-Sprintec. Davis's Drug Guide. F.A. Davis Company; 2024. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/61555/all/Tri_Sprintec. Accessed December 4, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Tri-Sprintec. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/61555/all/Tri_Sprintec
Vallerand AHA, Sanoski CAC, Quiring CC. Tri-Sprintec [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 December 04]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/61555/all/Tri_Sprintec.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tri-Sprintec
ID - 61555
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/61555/all/Tri_Sprintec
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -
